Therapeutic effect of caffeic acid phenethyl ester on cerulein-induced acute pancreatitis.
OBJECTIVE
To evaluate the therapeutic role of caffeic acid phenethyl ester (CAPE) in a rat model of cerulean-induced acute pancreatitis (AP).


METHODS
Seventy male Wistar albino rats were divided into seven groups. Acute edematous pancreatitis was induced by subcutaneous cerulein injection (20 microg/kg) four times at 1-h intervals. CAPE (30 mg/kg) was given by subcutaneous injection at the beginning (CAPE 1 group) and 12 h after the last cerulein injection (CAPE 2 group). Serum amylase, lipase, white blood cell count, and tumor necrosis factor (TNF)-alpha levels were measured, and pancreatic histopathology was assessed.


RESULTS
In the AP group, amylase and lipase levels were found to be elevated and the histopathological evaluation showed massive edema and inflammation of the pancreas, with less fatty necrosis when compared with sham and control groups. Amylase and lipase levels and edema formation decreased significantly in the CAPE therapy groups (P < 0001); especially in the CAPE 2 group, edema was improved nearly completely (P = 0001). Inflammation and fatty necrosis were partially recovered by CAPE treatment. The pathological results and amylase level in the placebo groups were similar to those in the AP group. White blood cell count and TNF-alpha concentration was nearly the same in the CAPE and placebo groups.


CONCLUSIONS
CAPE may be useful agent in treatment of AP but more experimental and clinical studies are needed to support our observation of beneficial effects of CAPE before clinical usage of this agent.
Buyukberber
Mehmet
M
Department of Gastroenterology, Gaziantep University, School of Medicine, 27310 Gaziantep, Turkey. mehmetbuyukberber@yahoo.com
Savaş
M Cemil
MC
Bagci
Cahit
C
Koruk
Mehmet
M
Gulsen
Murat T
MT
Tutar
Ediz
E
Bilgic
Tugba
T
Ceylan
Nurdan O
NO
D000208:Acute Disease; D000681:Amylases / Q000097:blood; D000818:Animals; D002109:Caffeic Acids / Q000627:therapeutic use*; D002108:Ceruletide / Q000009:adverse effects*; D003603:Cytotoxins / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004487:Edema / Q000473:pathology; D007958:Leukocyte Count; D008049:Lipase / Q000097:blood; D008297:Male; D010179:Pancreas / Q000473:pathology; D010195:Pancreatitis / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy*; D010626:Phenylethyl Alcohol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D002109:Caffeic Acids; D003603:Cytotoxins; D014409:Tumor Necrosis Factor-alpha; D002108:Ceruletide; D008049:Lipase; D000681:Amylases; C055494:caffeic acid phenethyl ester; D010626:Phenylethyl Alcohol